TrialBMC gastroenterology2021

Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.

Young-Il Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.